Non–Small Cell Lung Cancer Coverage from Every Angle


Refining Treatment of Oligometastatic NSCLC Is a Work in Progress
University of Utah Researchers Receive $2.6 Million Grant to Study Lung Tumor Biomechanics
Quality-of-Life Data Support Pembrolizumab’s Role in Early-Stage NSCLC
Use of Icotinib After Adjuvant Chemotherapy in EGFR-Mutated NSCLC
Health-Related Quality-of-Life Data From ALINA on Alectinib in NSCLC
Geriatric Assessment: Determining Optimal Treatment for Older Patients With NSCLC
Patient Education Initiative for Veterans With Non–Small Cell Lung Cancer
Bilobectomy vs Middle Lobe–Sparing Sleeve Resection for Central NSCLC of the Right Lower Lobe
Amivantamab Plus Lazertinib in High-Risk Subgroups With Advanced NSCLC
ASCO 2024: Study Analysis Focuses on Nodal Status With Neoadjuvant Nivolumab in Stage III NSCLC
ASCO 2024: Tumor-Treating Fields Therapy for Patients With NSCLC and Brain Metastases
Patient-Reported Outcomes: Wedge Resection vs Uniportal Thoracoscopic Segmentectomy for Peripheral NSCLC
ASCO 2024: New Antibody-Drug Conjugate Under Study in First Line for Advanced NSCLC
ASCO 2024: Air Pollution, Gene-Environment Interactions, and Risk of NSCLC in Nonsmokers
ASCO 2024: Novel KRAS G12C Inhibitor Plus Pembrolizumab for Advanced, Mutant NSCLC
ASCO 2024: CodeBreaK 101 Update on Sotorasib Plus Chemotherapy for Advanced NSCLC
ASCO 2024: Updated IMpower010 Survival Analysis of Atezolizumab in PD-L1–Positive NSCLC
ASCO 2024: Adagrasib vs Docetaxel in KRAS G12C–Mutated NSCLC
ASCO 2024: Subcutaneous vs Intravenous Amivantamab Combined With Lazertinib in NSCLC
ASCO 2024: Early Results From EVOKE-01 of Sacituzumab Govitecan in Metastatic NSCLC
ASCO 2024: Is Telehealth-Based Early Palliative Care Feasible in Advanced NSCLC?
ASCO 2024: Osimertinib After Chemoradiotherapy for EGFR-Mutated NSCLC
ASCO 2024: Long-Term Outcomes With Lorlatinib vs Crizotinib in ALK-Positive NSCLC
Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy for Resectable NSCLC
STK11 Mutations and Immunotherapeutic Efficacy in NSCLC
Case Study: Pathologic Complete Response After Triple-Induction Therapy for NSCLC
Insights Into NSCLC Management: Comprehensive Study Findings From South Korea
Can Oligoprogressive NSCLC Be Treated With Radiotherapy After Immunotherapy?
Does Thoracic Radiotherapy Induce Changes in Cardiac Morphology and Function?
Can Novel Methylation Biomarkers Enhance Lung Cancer Diagnosis via Bronchial Washing Samples?
ASCO Plenary Series: Phase II Study of Glecirasib in KRAS G12C–Mutated NSCLC
Molecular and Radiographic Biomarkers of Lung Cancer in Never-Smokers
AACR 2024: Can Ferroptosis Induction Overcome Chemoresistance in NSCLC?
AACR 2024: Indoor Aerosol Carcinogens and Nonsmoking-Related Lung Cancer
Alectinib Approved by FDA as Adjuvant Therapy for ALK-Positive NSCLC
AACR 2024: Estrogen Metabolites and Lung Cancer Among Never-Smokers
Does Vaping, in Addition to Smoking, Increase the Risk for Lung Cancer?
AACR 2024: New Data Reveal Mutagenic Forces May Cause Lung Cancer in Nonsmokers
Can Deep Learning Algorithm Predict Brain Metastasis in Patients With Lung Cancer?
Researchers Develop Novel Pan-Cancer Biomarker to Assess Tumor Microenvironment
SSO 2024: Is Image-Based Obesity Linked to Metabolic Pathway Alterations in NSCLC?
DNA Methylation: Researchers in Search of a Better Way to Screen for Lung Cancer
Are Immune-Related Adverse Events Associated With Overall Survival in NSCLC?
Understanding Acquired Resistance to Immunotherapy for NSCLC: Genomic and Immunophenotypic Insights
Updated Data on Entrectinib in NTRK Fusion–Positive NSCLC
ESMO Virtual Plenary: Neoadjuvant Tislelizumab Plus Chemotherapy and Adjuvant Tislelizumab for NSCLC
Racial Disparities in NSCLC: Biologic and Social Factors in Diagnosing Hispanic Individuals
FDA Approves Bispecific Antibody Plus Chemotherapy for EGFR Exon 20 Insertion–Mutated NSCLC
Using Deep Learning–Based Framework to Classify Lung Cancer Histology and Prognosis
FDA Brief: Breakthrough Therapy Designation Granted to Two Tyrosine Kinase Inhibitors in NSCLC
CheckMate 722: Final Results With Nivolumab Plus Chemotherapy in Metastatic NSCLC
Osimertinib With Chemotherapy Granted FDA Approval for EGFR-Mutated NSCLC
Cardiac Health and Lung Cancer Treatments: A Complex Balancing Act for Oncologists
FDA Approves Tepotinib for Metastatic NSCLC Harboring MET Exon 14 Skipping Alterations
Patient Age and Sex: Indicators for Segmentectomy vs Lobectomy in Pure-Solid NSCLC?
Is Medicaid Expansion Under the ACA Linked to Better Survival After Surgery for NSCLC?
STS 2024: Risk Factors and Predictors of VTE in Patients Undergoing Lung Cancer Surgery
Survey Says Medical Oncologists Favor More Research on Combination Therapies for Advanced NSCLC
NTRK Fusions in NSCLC: Improving Detection With Novel Methodology
DICER1 Hotspot Mutations in NSCLC: Clinical Implications for Genetic Testing
Using Machine Learning and CT Radiomics to Predict Brain Metastasis in Patients With NSCLC
Evaluating the Risk of Long QT Syndrome Risk in Older Patients Treated With Osimertinib for NSCLC
Could Adjuvant Chemotherapy Improve Survival Among High-Risk Patients With Stage IB NSCLC?
Targeted Therapies for NSCLC: Pathways to Fertility and Motherhood
Is First-Line Immunotherapy Efficacy Impacted by Race or Ethnicity in Advanced NSCLC?
Concurrent Chemoradiation With Dose-Escalation Ablative Radiotherapy for Unresectable NSCLC
Study Finds Clinical Benefit of Repotrectinib in ROS1 Fusion–Positive NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.